78 related articles for article (PubMed ID: 24111582)
1. Testosterone replacement therapy in hypogonadal men is associated with increased expression of LAMP-2 (CD107b) by circulating monocytes and dendritic cells.
Corrales JJ; Almeida M; Martín-Martín L; Miralles JM; Orfao A
Clin Endocrinol (Oxf); 2014 Apr; 80(4):577-84. PubMed ID: 24111582
[TBL] [Abstract][Full Text] [Related]
2. Enhanced immunological response by dendritic cells in male hypogonadism.
Corrales JJ; Almeida M; Cordero M; Martín-Martín L; Méndez C; Miralles JM; Orfao A
Eur J Clin Invest; 2012 Nov; 42(11):1205-12. PubMed ID: 22957648
[TBL] [Abstract][Full Text] [Related]
3. Persistence of androgenic effects on the production of proinflammatory cytokines by circulating antigen-presenting cells after withdrawal of testosterone treatment in aging type 2 diabetic men with partial androgen deficiency.
Corrales JJ; Almeida M; Miralles JM; Orfao A
Fertil Steril; 2009 Jul; 92(1):311-9. PubMed ID: 18710716
[TBL] [Abstract][Full Text] [Related]
4. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism.
Liao CH; Wu YN; Lin FY; Tsai WK; Liu SP; Chiang HS
Andrology; 2013 Jul; 1(4):563-9. PubMed ID: 23653307
[TBL] [Abstract][Full Text] [Related]
5. Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency.
Corrales JJ; Almeida M; Burgo R; Mories MT; Miralles JM; Orfao A
J Endocrinol; 2006 Jun; 189(3):595-604. PubMed ID: 16731790
[TBL] [Abstract][Full Text] [Related]
6. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement.
Ishizaka K; Suzuki M; Kageyama Y; Kihara K; Yoshida K
Asian J Androl; 2002 Jun; 4(2):117-21. PubMed ID: 12085102
[TBL] [Abstract][Full Text] [Related]
8. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
[TBL] [Abstract][Full Text] [Related]
9. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
10. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy.
Lanfranco F; Zitzmann M; Simoni M; Nieschlag E
Clin Endocrinol (Oxf); 2004 Apr; 60(4):500-7. PubMed ID: 15049966
[TBL] [Abstract][Full Text] [Related]
11. A small-scale clinical trial to determine the safety and efficacy of testosterone replacement therapy in hypogonadal men with spinal cord injury.
Bauman WA; Cirnigliaro CM; La Fountaine MF; Jensen AM; Wecht JM; Kirshblum SC; Spungen AM
Horm Metab Res; 2011 Jul; 43(8):574-9. PubMed ID: 21717386
[TBL] [Abstract][Full Text] [Related]
12. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
Morrison BF; Reid M; Madden W; Burnett AL
Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
[TBL] [Abstract][Full Text] [Related]
13. Testosterone supplementation does not worsen lower urinary tract symptoms.
Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT
J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
[TBL] [Abstract][Full Text] [Related]
14. Testosterone administration in older men.
Matsumoto AM
Endocrinol Metab Clin North Am; 2013 Jun; 42(2):271-86. PubMed ID: 23702401
[TBL] [Abstract][Full Text] [Related]
15. Testosterone concentrations in hair of hypogonadal men with and without testosterone replacement therapy.
Thomson S; Koren G; Van Steen V; Rieder M; Van Uum SH
Ther Drug Monit; 2009 Dec; 31(6):779-82. PubMed ID: 19809386
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
18. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy.
Hsieh TC; Pastuszak AW; Hwang K; Lipshultz LI
J Urol; 2013 Feb; 189(2):647-50. PubMed ID: 23260550
[TBL] [Abstract][Full Text] [Related]
19. Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS).
Blick G; Khera M; Bhattacharya RK; Nguyen D; Kushner H; Miner MM
Pain Med; 2012 May; 13(5):688-98. PubMed ID: 22536837
[TBL] [Abstract][Full Text] [Related]
20. Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections.
Rochira V; Balestrieri A; Madeo B; Granata AR; Carani C
J Androl; 2006; 27(2):165-75. PubMed ID: 16278367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
